PBAC's latest decision on Eletriptan hydrobromide: Recommended with restriction (2010). Considered for treatment of migraine attacks in patients where past attacks have usually failed to respond to analgesics.
PBAC outcome
Recommended with restriction
Authority Required (Streamlined)
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2010
Submissions
1
2010 → 2010
Eligible population
patients where attacks in the past have usually failed to respond to analgesics
Therapy area
Pain
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
OS | PFS | DFS | ORR | QoL | Surrogate | Cost-minimisation | Other | null
Pivotal trial size
1,250 patients
Key trials
Study A160-314, Study A160-1048, Study A160-318
Comparator
sumatriptan
Economic model
Cost-minimisation
ICER note
Cost minimisation analysis conducted; no ICER calculated